ArticleRSC advances2026
Molecular and physicochemical arrangement of chitosan-ibuprofen matrices for topical drug delivery on skin: preparation impact.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tannic Acid-Copper Coordination Gel-Coated Mesoporous Cuprous Oxide Nanoplatform for Synergistic 5-FU Chemotherapy and Enhanced Chemodynamic Therapy.Gels (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in modern medicine emphasize patient-centric and personalized therapeutic strategies, particularly for chronic and regenerative applications. Among emerging biomaterials, chitosan (CS) has gained considerable attention due to its biocompatibility, biodegradability, and antimicrobial properties, while its molecular weight strongly influences structural organization and interactions with active compounds. In this study, chitosan-based matrices-2% (w/v) low-molecular-weight CS, 4% (w/v) low-molecular-weight CS, and 2% (w/v) medium-molecular-weight CS-were developed and enriched with ibuprofen (IBU), a widely used non-steroidal anti-inflammatory drug, to improve topical delivery and reduce systemic side effects. The physicochemical properties of gelled thin films were investigated with emphasis on molecular arrangement, surface characteristics, and drug release behavior in phosphate-buffered saline. ATR-FTIR spectroscopy, contact angle measurements, and atomic force microscopy (AFM) were employed to evaluate structural and functional changes induced by IBU incorporation. Medium-molecular-weight CS exhibited lower water contact angles (≈69-73°) and higher surface free energy (≈41-44 mN m
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.